The U.S. Food and Drug Administration has approved Regeneron Pharmaceuticals' Lynozyfic, a therapy for recurrent multiple myeloma, boosting the company's shares by 2%.

Regeneron Pharmaceuticals gains FDA approval for Lynozyfic drug targeting multiple myeloma, with launch details and executive ...

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

BWX Technologies, Inc. (NYSE:BWXT) is one of the top 10 nuclear energy stocks to invest in for the next decade. On June 5, ...

The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.